They demonstrated that this resistance could be overcome by anti-miR-221/222 and anti-miR-30c, which recovered the expression of the pro-apoptotic protein BCL2L11 (BIM) and increased the gefitinib sensitivity of NSCLC both in vitro and in vivo. This evidence concerns the gene BCL2L11 and non-small cell lung carcinoma.